Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=653). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Please download to know all details of the Special Issue
The aim of this issue would be to evaluate the basic science and clinical implications of psychedelic use as an emerging therapy in psychiatric conditions. The pathophysiology of the various agents being studied across the world will be reviewed and included so as to offer insight into their influence on the brain (in regards to neural connectivity, neural activation, and molecular processing) and subsequent effect on disorders including but not limited to depression, anxiety, and addiction. There has been increasing discussion and debate over how many of these substances (psilocybin, lysergic acid diethylamide, N, N- Dimethyltryptamine, 3, 4- Methylenedioxymethamphetamine, and their active metabolites) may play a role in the treatment of psychiatric conditions. Much of the information available relies solely on clinical data, with there being a dearth of published data on the underlying mechanisms of these potential therapies, including functional neuroimaging and molecular studies that should be emphasized in this issue. However, clinical data underscoring the effects, risks, and benefits of these potential treatments are welcome as well. Concurrently, philosophical approaches to the use of psychedelics and conditions where they may be indicated will be examined, as is necessary in addressing these emerging and controversial treatments. There also exists potential to include information from varying philosophical perspectives and logistical complications in providing these therapies including legislative and systems issues that continue to impact scientific research and clinical care.
In summary the journal issue chiefly will:
present emerging research on the pathophysiology of psychedelic compounds on the human brain and in animal models
examine functional neuroimaging to elucidate the effect of psychedelic compounds
review previous literature on the fundamental science and clinical findings of psychedelics in clinical practice
assess philosophical approaches of the nosology and treatment for psychiatric illnesses with psychedelic compounds
discuss ethical and logistical complications of the implementation of psychedelics